专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07482004B2 Inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumor formation and/or vascular leakage 有权
标题翻译：胎盘生长因子抑制剂用于治疗病理性血管生成，病理性动脉生成，炎症，肿瘤形成和/或血管渗漏
公开(公告)号：US07482004B2
公开(公告)日：2009-01-27
申请号：US10291979
申请日：2002-11-11
申请人： Peter Carmeliet , Désiré Collen , Sandro De Falco , Ruvo Menotti
发明人： Peter Carmeliet , Désiré Collen , Sandro De Falco , Ruvo Menotti
IPC分类号： A61K39/395
CPC分类号： C07K16/22 , A61K38/07 , A61K39/3955 , A61K2039/505 , C07K1/047 , G01N2333/71
摘要： The present invention relates to the field of pathological angiogenesis and arteriogenesis and, in particular, to a stress-induced phenotype in a transgenic mouse (PIGF−/−) that does not produce Placental Growth Factor (PIGF) and that demonstrates an impaired vascular endothelial growth factor (VEGF)-dependent response. PIGF deficiency has a negative influence on diverse pathological processes of angiogenesis, arteriogenesis and vascular leakage comprising ischemic retinopathy, tumor formation, pulmonary hypertension, vascular leakage (edema formation) and inflammatory disorders. The invention thus relates to molecules that can inhibit the binding of PIGF to its receptor (VEGFR-1), such as monoclonal antibodies and tetrameric peptides, and to the use of these molecules to treat the above-mentioned pathological processes.
摘要翻译：本发明涉及病理性血管发生和动脉发生的领域，特别涉及不产生胎盘生长因子（PIGF）的转基因小鼠（PIGF - / - ）中的应激诱导表型，并且证明了受损的血管内皮生长因子（VEGF）依赖性反应。 PIGF缺陷对包括缺血性视网膜病变，肿瘤形成，肺动脉高压，血管渗漏（水肿形成）和炎性疾病的血管生成，动脉发生和血管渗透的多种病理过程具有负面影响。因此，本发明涉及可以抑制PIGF与其受体（VEGFR-1）如单克隆抗体和四聚体肽的结合的分子，以及这些分子用于治疗上述病理过程的分子。

2. 发明申请

US20130183310A1 ADMINISTERING ANTI-PLACENTAL GROWTH FACTOR ANTIBODIES 审中-公开
公开(公告)号：US20130183310A1
公开(公告)日：2013-07-18
申请号：US13785643
申请日：2013-03-05
申请人： Peter Carmeliet , Desire Collen , Sandro De Falco , Ruvo Menotti
发明人： Peter Carmeliet , Desire Collen , Sandro De Falco , Ruvo Menotti
IPC分类号： C07K16/22
CPC分类号： C07K16/22 , A61K38/07 , A61K39/3955 , A61K2039/505 , C07K1/047 , G01N2333/71
摘要： The present invention relates to the field of pathological angiogenesis and arteriogenesis and, in particular, to a stress-induced phenotype in a transgenic mouse (PIGF−/−) that does not produce Placental Growth Factor (PIGF) and that demonstrates an impaired vascular endothelial growth factor (VEGF)-dependent response. PIGF deficiency has a negative influence on diverse pathological processes of angiogenesis, arteriogenesis and vascular leakage comprising ischemic retinopathy, tumor formation, pulmonary hypertension, vascular leakage (edema formation) and inflammatory disorders. The invention thus relates to molecules that can inhibit the binding of PIGF to its receptor (VEGFR-1), such as monocloncal antibodies and tetrameric peptides, and to the use of these molecules to treat the above-mentioned pathological processes.

3. 发明授权

US07888322B2 Use of VEGF and homologues to treat neuron disorders 有权
公开(公告)号：US07888322B2
公开(公告)日：2011-02-15
申请号：US12313338
申请日：2008-11-19
申请人： Peter Carmeliet , Désiré Collen , Bert Oosthuyse
发明人： Peter Carmeliet , Désiré Collen , Bert Oosthuyse
IPC分类号： A61K38/18 , C07K14/475
CPC分类号： A01K67/0276 , A01K2217/075 , A01K2227/105 , A01K2267/0312 , A01K2267/0318 , A01K2267/0356 , A61K38/1866 , A61K48/00 , C07K14/52 , C12N15/8509 , C12N2800/30 , C12N2830/002 , C12N2830/85
摘要： The present invention relates to neurological and physiological dysfunction associated with neuron disorders. In particular, the invention relates to the involvement of vascular endothelial growth factor (VEGF) and homologues in the aetiology of motor neuron disorders. The invention further concerns a novel, mutant transgenic mouse (VEGFm/m) with a homozygous deletion in the hypoxia responsive element (HRE) of the VEGF promoter which alters the hypoxic upregulation of VEGF. These mice suffer severe adult onset muscle weakness due to progressive spinal motor neuron degeneration which is reminiscent of amyotrophic lateral sclerosis (ALS)—a fatal disorder with unknown aetiology. Furthermore, the neuropathy of these mice is not caused by vascular defects, but is due to defective VEGF-mediated survival signals to motor neurons. The present invention relates in particular to the isoform VEGF165 which stimulates survival of motor neurons via binding to neuropilin-1, a receptor known to bind semaphorin-3A which is implicated in axon retraction and neuronal death, and the VEGF Receptor-2. The present invention thus relates to the usage of VEGF, in particular VEGF165, for the treatment of neuron disorders and relates, in addition, to the usage of polymorphisms in the VEGF promotor for diagnosing the latter disorders.

4. 发明授权

US07226908B2 Use of VEGF and homologues to treat neuron disorders 有权
标题翻译：使用VEGF和同系物治疗神经元疾病
公开(公告)号：US07226908B2
公开(公告)日：2007-06-05
申请号：US10257423
申请日：2001-04-12
申请人： Peter Carmeliet , Désiré Collen , Bert Oosthuyse
发明人： Peter Carmeliet , Désiré Collen , Bert Oosthuyse
IPC分类号： A61K38/18 , C07K14/475
CPC分类号： A01K67/0276 , A01K2217/075 , A01K2227/105 , A01K2267/0312 , A01K2267/0318 , A01K2267/0356 , A61K38/1866 , A61K48/00 , C07K14/52 , C12N15/8509 , C12N2800/30 , C12N2830/002 , C12N2830/85
摘要： The present invention relates to neurological and physiological dysfunction associated with neuron disorders. In (particular, the invention relates to the involvement of vascular endothelial growth factor (VEGF) and homologues in the aetiology of motor neuron disorders. The invention further concerns a novel, mutant transgenic mouse (VEGFm/m) with a homozygous deletion in the hypoxia responsive element (HRE) of the VEGF promoter which alters the hypoxic upregulation of VEGF. These mice suffer severe adult onset muscle weakness due to progressive spinal motor neuron degeneration which is reminiscent of amyotrophic lateral sclerosis (ALS)—a fatal disorder with unknown aetiology. Furthermore, the neuropathy of these mice is not caused by vascular defects, but is due to defective VEGF-mediated survival signals to motor neurons. The present invention relates in particular to the isoform VEGF165 which stimulates survival of motor neurons via binding to neuropilin-1, a receptor known to bind semaphorin-3A which is implicated in axon retraction and neuronal death, and the VEGF Receptor-2. The present invention thus relates to the usage of VEGF, in particular VEGF165, for the treatment of neuron disorders and relates, in addition, to the usage of polymorphisms in the VEGF promotor for diagnosing the latter disorders.
摘要翻译：本发明涉及与神经元疾病相关的神经和生理功能障碍。（特别是本发明涉及血管内皮生长因子（VEGF）和同系物参与运动神经元病症的病因，本发明还涉及一种新型突变型转基因小鼠（VEGF m / ）在VEGF启动子的缺氧应答元件（HRE）中具有纯合缺失，其改变VEGF的缺氧上调，这些小鼠由于进行性脊髓运动神经元变性而受到严重的成年发作性肌无力，这使人想起肌萎缩性侧索硬化（ALS）此外，这些小鼠的神经病变不是由血管缺陷引起的，而是由于VEGF介导的对运动神经元的存活信号的缺陷。本发明特别涉及同种型VEGF 165 其通过结合神经胶质蛋白-1刺激运动神经元的存活，神经胶质蛋白-1是已知结合轴突回缩和神经元死亡的信号素-3A的受体，以及VEGF Re ceptor-2。因此，本发明涉及VEGF，特别是VEGF 165用于治疗神经元病症的用途，此外还涉及VEGF启动子中用于诊断后一种疾病的多态性的用途。

5. 发明授权

US07105168B1 Method of improving ischemic muscle function by administering placental growth factor 有权
标题翻译：通过施用胎盘生长因子来改善缺血肌肉功能的方法
公开(公告)号：US07105168B1
公开(公告)日：2006-09-12
申请号：US10454242
申请日：2003-06-04
申请人： Peter Carmeliet , Désiré Collen
发明人： Peter Carmeliet , Désiré Collen
IPC分类号： A61K38/18 , C07K14/475
CPC分类号： A61K38/1866
摘要： The present invention relates to prevention and treatment of strokes and ischemic diseases and to post-ischemic therapeutic treatment. The invention furthermore relates to the use of a growth factor for treating, more particularly restoring the function of ischemic tissue, in particular muscles such as myocardium and skeletal muscles.
摘要翻译：本发明涉及中风和缺血性疾病的预防和治疗以及缺血后治疗的治疗。本发明还涉及生长因子用于治疗，更具体地恢复缺血组织，特别是肌肉如心肌和骨骼肌的功能的用途。

6. 发明授权

US08758748B2 Anti-angiogenic therapy 有权
标题翻译：抗血管生成治疗
公开(公告)号：US08758748B2
公开(公告)日：2014-06-24
申请号：US12973155
申请日：2010-12-20
申请人： Jean-Marie Stassen , Peter Carmeliet , Désiré Collen
发明人： Jean-Marie Stassen , Peter Carmeliet , Désiré Collen
IPC分类号： A61K39/395
CPC分类号： C07K16/22 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/24
摘要： The present invention provides novel monoclonal antibodies directed to PlGF and fragments and derivatives thereof, more particularly to humanized antibodies and fragments thereof for use in the treatment and/or prevention of pathological angiogenesis.
摘要翻译：本发明提供了针对PlGF及其片段和衍生物的更新的单克隆抗体，更具体地提供用于治疗和/或预防病理性血管生成的人源化抗体及其片段。

7. 发明申请

US20110123525A1 ANTI-ANGIOGENIC THERAPY 有权
标题翻译：抗生素治疗
公开(公告)号：US20110123525A1
公开(公告)日：2011-05-26
申请号：US12973155
申请日：2010-12-20
申请人： Jean-Marie Stassen , Peter Carmeliet , Désiré Collen
发明人： Jean-Marie Stassen , Peter Carmeliet , Désiré Collen
IPC分类号： A61K39/395 , A61P35/00 , A61P9/00 , A61P27/02 , A61P11/00 , A61P29/00 , A61P19/00
CPC分类号： C07K16/22 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/24
摘要： The present invention provides novel monoclonal antibodies directed to PlGF and fragments and derivatives thereof, more particularly to humanized antibodies and fragments thereof for use in the treatment and/or prevention of pathological angiogenesis.
摘要翻译：本发明提供了针对PlGF及其片段和衍生物的更新的单克隆抗体，更具体地提供用于治疗和/或预防病理性血管生成的人源化抗体及其片段。

8. 发明授权

US07357929B2 Placental growth factor as a target for the treatment of osteoporosis 有权
标题翻译：胎盘生长因子作为治疗骨质疏松症的目标
公开(公告)号：US07357929B2
公开(公告)日：2008-04-15
申请号：US10519330
申请日：2003-06-27
申请人： Peter Carmeliet , Désiré Collen , Roger Bouillon , Gertrudis Carmeliet
发明人： Peter Carmeliet , Désiré Collen , Roger Bouillon , Gertrudis Carmeliet
IPC分类号： A61K39/00 , C07K14/475
CPC分类号： C07K16/2863 , A61K2039/505 , C07K16/22 , C07K2317/34
摘要： This invention relates to antagonists of placental growth factor and signalling thereof, pharmaceutical compositions containing such antagonists and the use of such antagonists to prevent bone loss or bone mass and to enhance bone healing including the treatment of conditions which present with low bone mass and/or bone defects in vertebrates, and particularly mammals, including humans.
摘要翻译：本发明涉及胎盘生长因子及其信号传导的拮抗剂，含有这些拮抗剂的药物组合物以及这种拮抗剂用于预防骨丢失或骨量并增强骨愈合的用途，包括治疗以低骨量和/或脊椎动物，特别是哺乳动物，包括人类的骨缺损。

9. 发明申请

US20110288020A1 Use of VEGF and homologues to treat neuron disorders 审中-公开
标题翻译：使用VEGF和同系物治疗神经元疾病
公开(公告)号：US20110288020A1
公开(公告)日：2011-11-24
申请号：US12928131
申请日：2010-12-03
申请人： Peter Carmeliet , Désiré Collen , Bert Oosthuyse
发明人： Peter Carmeliet , Désiré Collen , Bert Oosthuyse
IPC分类号： A61K38/18 , A61P25/00 , C12Q1/02 , A61K31/7088
CPC分类号： A01K67/0276 , A01K2217/075 , A01K2227/105 , A01K2267/0312 , A01K2267/0318 , A01K2267/0356 , A61K38/1866 , A61K48/00 , C07K14/52 , C12N15/8509 , C12N2800/30 , C12N2830/002 , C12N2830/85
摘要： The present invention relates to neurological and physiological dysfunction associated with neuron disorders. In particular, the invention relates to the involvement of vascular endothelial growth factor (VEGF) and homologues in the aetiology of motor neuron disorders. The invention further concerns a novel, mutant transgenic mouse (VEGFm/m) with a homozygous deletion in the hypoxia responsive element (HRE) of the VEGF promoter which alters the hypoxic upregulation of VEGF. These mice suffer severe adult onset muscle weakness due to progressive spinal motor neuron degeneration which is reminiscent of amyotrophic lateral sclerosis (ALS)—a fatal disorder with unknown aetiology. Furthermore, the neuropathy of these mice is not caused by vascular defects, but is due to defective VEGF-mediated survival signals to motor neurons. The present invention relates in particular to the isoform VEGF165 which stimulates survival of motor neurons via binding to neuropilin-1, a receptor known to bind semaphorin-3A which is implicated in axon retraction and neuronal death, and the VEGF Receptor-2. The present invention thus relates to the usage of VEGF, in particular VEGF165, for the treatment of neuron disorders and relates, in addition, to the usage of polymorphisms in the VEGF promotor for diagnosing the latter disorders.
摘要翻译：本发明涉及与神经元疾病相关的神经和生理功能障碍。特别地，本发明涉及血管内皮生长因子（VEGF）和同系物参与运动神经元疾病的病因学。本发明还涉及在VEGF启动子的缺氧应答元件（HRE）中具有纯合缺失的新型突变转基因小鼠（VEGFm / m），其改变VEGF的缺氧上调。这些小鼠由于进行性脊髓运动神经元变性而遭受严重的成人发作肌肉无力，其使人想起肌萎缩性侧索硬化（ALS） - 一种具有未知病因的致命性疾病。此外，这些小鼠的神经病变不是由血管缺陷引起的，而是由于VEGF介导的运动神经元的生存信号。本发明特别涉及通过与神经胶蛋白-1结合来刺激运动神经元的存活的同种型VEGF165，该神经蛋白-1是已知结合轴突回缩和神经元死亡的信号素-3A的受体以及VEGF受体-2。因此，本发明涉及VEGF，特别是VEGF165用于治疗神经元病症的用途，此外还涉及VEGF启动子中用于诊断后一种疾病的多态性的用途。

10. 发明授权

US07727971B2 Use of placental growth factor for treating ischemic muscle disease 失效
标题翻译：使用胎盘生长因子治疗缺血性肌肉病
公开(公告)号：US07727971B2
公开(公告)日：2010-06-01
申请号：US11471823
申请日：2006-06-21
申请人： Peter Carmeliet , Désiré Collen
发明人： Peter Carmeliet , Désiré Collen
IPC分类号： A61K48/00 , A01N63/00
CPC分类号： A61K38/1866 , A61K48/00
摘要： The present invention relates to prevention and treatment of strokes and ischemic diseases and to post-ischemic therapeutic treatment. The invention furthermore relates to the use of a growth factor or nucleic acids ensuring increased expression of a growth factor for treating, more particularly restoring the function of ischemic tissue, in particular muscles such as myocardium and skeletal muscles.
摘要翻译：本发明涉及中风和缺血性疾病的预防和治疗以及缺血后治疗的治疗。本发明还涉及生长因子或核酸的使用，其确保用于治疗，更具体地恢复缺血组织，特别是肌肉如心肌和骨骼肌的功能的生长因子的增加的表达。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式